Dr. Paul A. Friedman Joins Verastem Board of Directors
Business Wire - Mon May 12, 3:00PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the appointment of Paul A. Friedman, M.D. to its Board of Directors.
Verastem Announces Initiation of COMMAND Study in Japan
Business Wire - Mon May 12, 6:01AM CDT
--Allowance by the PMDA Enables Verastem to Pursue Parallel Development in the Major Markets Worldwide -
Verastem Reports First Quarter 2014 Financial and Corporate Results
Business Wire - Thu May 08, 3:14PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the first quarter ended March 31, 2014, and also provided an update of certain corporate accomplishments and plans.
Verastem to Present at Upcoming Conferences
Business Wire - Wed Apr 30, 6:01AM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will participate at several upcoming conferences. The presentation details are as follows:
Global Malignant Pleural Mesothelioma Clinical Trials Review 2014 - Overview of the Top 19 Companies/Institutions
M2 - Tue Apr 29, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t5t4hg/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Pleural Mesothelioma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Pleural Mesothelioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Pleural Mesothelioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Pleural Mesothelioma. Clinical Trial Overview of Top Companies/Institutions - Eli Lilly and Company - Novartis AG - Verastem, Inc. - MolMed S.p.A. - Merck & Co., Inc. - Virttu Biologics Limited - Polaris Group - Boehringer Ingelheim GmbH - AstraZeneca PLC - Aduro BioTech, Inc. - National Cancer Institute - Memorial Sloan Kettering Cancer Center - European Organization for Research and Treatment of Cancer - Istituto Clinico Humanitas - The University of Texas M. D. Anderson Cancer Center - Columbia University - Abramson Cancer Center - Hyogo College Of Medicine - University Health Network For more information visit http://www.researchandmarkets.com/research/t5...nt_pleural
Malignant Mesothelioma Therapeutics Pipeline Review 2014 - Analysis of 13 Companies & 22 Drug Profiles
M2 - Tue Apr 22, 4:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/db52sm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - MedImmune, LLC - Aduro BioTech, Inc. - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Advantagene, Inc. - Y's Therapeutics Co., Ltd. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - AEOL-10150 - Ad5-SGE-REIC/Dkk3 Gene Therapy - BAY-949343 - BERTA - BIW-8962 - BNC-105 - Bivalent Bispecific Tribody - CRS-207 - Drug For Mesothelioma - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - FPI-01 - LY-3023414 - Monovalent Trispecific Tribody - Oshadi D - Oshadi D Oshadi R - SentoClone - VS-4718 - YP-223 - YP-3 - YS-110 - YYP-218 - tremelimumab For more information visit http://www.researchandmarkets.com/research/db52sm/malignant
Global Malignant Mesothelioma Clinical Trials Review 2014 - Profiles of 10 Companies & 9 Organisations
M2 - Thu Apr 17, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/llpnwn/malignant) has announced the addition of the "Malignant Mesothelioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Mesothelioma Global Clinical Trials Review, H1, 2014 provides data on the Malignant Mesothelioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Mesothelioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Mesothelioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Eli Lilly and Company - Novartis AG - Verastem, Inc. - Merck & Co., Inc. - AstraZeneca PLC - Polaris Group - MolMed S.p.A. - Eisai Inc. - Aduro BioTech, Inc. - Anza Therapeutics, Inc. - National Cancer Institute - Memorial Sloan Kettering Cancer Center - European Organization for Research and Treatment of Cancer - The University of Texas M. D. Anderson Cancer Center - Columbia University - Istituto Clinico Humanitas - Fox Chase Cancer Center - Stanford University - University Health Network For more information visit http://www.researchandmarkets.com/research/llpnwn/malignant
Verastem Presents Data on Cancer Stem Cell-Targeting Agents at the 2014 AACR Annual Meeting
Business Wire - Wed Apr 09, 6:00AM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the presentation of scientific data at the American Association for Cancer Research annual meeting being held April 5 - 9, 2014, at the San Diego Convention Center in San Diego, CA.
Verastem to Present Data on Product Candidates Targeting Cancer Stem Cells at the American Association of Cancer Research Meeting
Business Wire - Tue Mar 25, 6:00AM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present data at the upcoming American Association of Cancer Research (AACR) meeting to be held April 5-9, 2014 at the San Diego Convention Center in San Diego, CA.
Cancer Stem Cell Trends & Designs of Novel Drugs Featuring Major Players Boston Biomedical, Macrogenics & Verastem
M2 - Fri Mar 21, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ggdxn5/cancer_stem_cell) has announced the addition of the "Cancer Stem Cell Trends" report to their offering. The report illustrates on the growing market for Cancer Stem Cells (CSCs) in the US and Europe The major factors stimulating the growth of the market are the rising affliction of diseases such as cancer and the reimbursement assistance by regulatory organizations in developed nations including the US and Europe. Cancer Stem Cells (CSCs) are the cells within a tumor that possess the capability of self-renewal and driving tumorigenesis. In the previous research studies, rare CSCSs have been isolated from several human tumors such as brain, breast, colon and haematopoietic cancers. CSCs are believed to survive in tumors as a completely distinct population and might cause metastasis and relapse by producing new tumors. In addition, the report highlights the exponential rise in research on Cancer Stem Cells (CSCs), and the design of novel drugs to treat CSCs. Major players in the field include Boston Biomedical Inc., Macrogenics, and Verastem, Inc. Key Topics Covered: 1. CANCER STEM CELLS - A FOCUS REPORT - Prelude - CSC Hypothesis - An Overview - Impact on Pharmacology Research and Modern Molecular Physiology - Limitations and Inconsistencies - Origin of CSCs Remains Elusive - CSC In Vitro Models - Cells from Tumor Lines - Genetic Manipulation of Cell Lines - Sorted Tumor Cells Selection - Properties of CSCs - Identification and Characterization of CSCs - Elimination of CSCs - The Key in Preventing Tumor Reappearance 2. TECHNOLOGY OVERVIEW - Research on Cancer Stem Cell Accelerates - Existence of CSCs - A Topic of Debate - Hype Surrounding CSC Research Fails to Fetch End Results - Mathematical Models - Cellular Pathways - CSCs and the Wnt Pathway - Focal Adhesion Kinase (FAK) - Future of CSC Research 3. MARKET INFORMATION - Cancer Stem Cells and Circulating Tumor Cells Market 4. NOTEWORTHY MARKET PARTICIPANTS - Boston Biomedical, Inc. (USA) - Macrogenics (USA) - Verastem, Inc. (USA) 5. CORPORATE/RESEARCH INITIATIVES - Bionomics Acquires Eclipse Therapeutics - Dainippon Sumitomo Pharma Acquires Boston Biomedical - Queensland University Scientists to Study Ovarian CSCs - Sanford-Burnham Researchers Study Isolated Ovarian CSCs - Harvard Medical School Researchers Suspect Radiotherapy and Chemotherapy in Development of CSCs - Mount Sinai School of Medicine Leads Research on CSCs to Develop New Therapies - University of Texas Scientists Research to Arrest Cancer Re- growth - McMaster's Stem Cell and Cancer Research Institute Scientists Discover Thioridazine's Potential to Kill CSCs - Ohio State University College of Medicine Proposes Cancer Stem Cells (CSCs) Theory - Research Collaboration Identifies Potential of Gamma-Tocotrienol - Research on Maintenance Mechanism by Cancers - Verastem to Develop Drugs Targeting Cancer Stem Cells - University of Michigan Researchers Study the Role of Cancer Stem Cells in Ovarian Cancer - Hong Kong Researchers Find CSCs with CD24 Surface Protein Aggravate Liver Cancer - CRUK to Research on Cancer-Combating Drugs - University of Michigan Researchers Use Experimental Drugs to Inhibit Breast Cancer - University of Pittsburgh Researchers Discover Prevention of Isolated CSCs from Differentiating 6. APPENDIX For more information visit http://www.researchandmarkets.com/research/gg..._stem_cell
Verastem to Present at the Boston Business Development Conference
Business Wire - Thu Mar 20, 6:00AM CDT
Verastem, Inc., (NASDAQ:VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be participating in the upcoming Boston Business Development Conference on Tuesday and Wednesday, March 25-26, 2014. The conference will take place at The Four Seasons Hotel in Boston.
Timothy J. Barberich Joins Verastem Board of Directors
Business Wire - Tue Mar 11, 6:00AM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the appointment of Timothy J. Barberich to its Board of Directors.
Verastem Reports Year-End 2013 Financial Results
Business Wire - Thu Mar 06, 6:00AM CST
--Multiple clinical data readouts anticipated starting in first half 2014--
Verastem Reports Data from Phase 1 Study of VS-6063 (defactinib) in Japanese Patients
Business Wire - Wed Mar 05, 4:00PM CST
--- Results Facilitate Potential Parallel Development of VS-6063 (defactinib) in Japan -
Verastem to Present at Upcoming Investor Conferences
Business Wire - Tue Mar 04, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at upcoming investor conferences. The presentation details are as follows:
Verastem Supports Worldwide Rare Disease Day on February 28, 2014
Business Wire - Fri Feb 28, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced its support of the rare disease awareness events being held globally. Verastem's lead compound targeting cancer stem cells, VS-6063, is currently in the registration-directed COMMAND study and has been granted orphan drug designation in the U.S. and E.U. for use in mesothelioma.
Verastem to Present at Upcoming Scientific Conferences
Business Wire - Wed Feb 26, 3:01PM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at two upcoming scientific conferences, including the 12th International Congress on Targeted Anticancer Therapies (TAT), where a poster with data from a Phase 1 trial of VS-6063 (defactinib), a potent inhibitor of focal adhesion kinase (FAK), in Japanese patients with advanced solid tumors will be presented. The presentation details are as follows:
Today's Biggest Biotech Stories: BioCryst, Verastem, and InterMune
Leo Sun, The Motley Fool - Motley Fool - Tue Feb 25, 8:35AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a...
Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718
Business Wire - Tue Feb 25, 6:01AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it has acquired the license to VS-4718 held originally by Poniard Pharmaceuticals. The previous and future developmental, regulatory and commercial royalty milestones and payments associated with the development and potential future sales of VS-4718 due to Poniard Pharmaceuticals are now owned by Verastem. Verastem retains a license to VS-4718 from The Scripps Research Institute.